NANOMIX CORP
BTHI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BTHI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
bti-320 (Phase 2)
Next Catalyst
—
Financial data as of Dec 31, 2022.
Tracking 3 pipeline candidates for NANOMIX CORP.
Run NANOMIX CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NANOMIX CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
N/A
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is NANOMIX CORP's lead drug candidate?
NANOMIX CORP's most advanced tracked candidate is bti-320 (Phase 2) for Type 2 diabetes and partial weight management.
What therapeutic areas does NANOMIX CORP focus on?
NANOMIX CORP develops therapies across Neurology, Infectious Disease, Metabolic, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.